menu
    • menu

    Company profile for Electra Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells, and deplet...
    Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells, and depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Electra TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    681 Gateway Blvd. South San Francisco, CA 94080
    Telephone
    Telephone
    888-743-2290
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://electra-therapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Electra Therapeutics Initiates ELA026 Study In SHLH Phase 2/3
    Electra Therapeutics Initiates ELA026 Study In SHLH Phase 2/3

    22 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/22/3170939/0/en/Electra-Therapeutics-Announces-First-Patients-Dosed-in-the-SURPASS-Phase-2-3-Pivotal-Study-of-ELA026-in-Secondary-Hemophagocytic-Lymphohistiocytosis-sHLH.html

    GLOBENEWSWIRE
    22 Oct 2025
    Share Share
    Electra Therapeutics Granted FDA Breakthrough & EMA Priority
    Electra Therapeutics Granted FDA Breakthrough & EMA Priority

    22 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/22/3170930/0/en/Electra-Therapeutics-Receives-FDA-Breakthrough-Therapy-and-EMA-Priority-Medicines-Designations-for-ELA026-in-Secondary-Hemophagocytic-Lymphohistiocytosis-sHLH.html

    GLOBENEWSWIRE
    22 Oct 2025
    Share Share
    Electra shines with $183M fundraise for rare disease trial
    Electra shines with $183M fundraise for rare disease trial

    22 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/22/3170938/0/en/Electra-Therapeutics-Announces-183-Million-Series-C-Financing-to-Advance-First-in-Class-SIRP-Targeted-Therapies-for-Immune-Disorders-and-Cancer.html

    GLOBENEWSWIRE
    22 Oct 2025
    Share Share
    Electra Therapeutics to Present at 43rd J.P. Morgan Conference
    Electra Therapeutics to Present at 43rd J.P. Morgan Conference

    06 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250106057703/en

    BUSINESSWIRE
    06 Jan 2025
    Share Share
    Electra Presents Positive Phase 1b Results in sHLH at ASH 2024
    Electra Presents Positive Phase 1b Results in sHLH at ASH 2024

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241209017273/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    Electra Therapeutics Presents ELA026 Results in sHLH at ASH 2024
    Electra Therapeutics Presents ELA026 Results in sHLH at ASH 2024

    05 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241104570230/en

    BUSINESSWIRE
    05 Nov 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search